Skip to main content
SpringerLink
Log in

FDG-PET/CT in Lymphoma

  • Protocol
  • First Online:
Positron Emission Tomography

Part of the book series: Methods in Molecular Biology ((MIMB,volume 727))

Abstract

Molecular Imaging has played a prominent role in the assessment of lymphoma for now almost three decades since the introduction of 67Ga-citrate imaging for staging and restaging of both Hodgkin’s and non-Hodgkin’s lymphoma (HL and NHL). Since then other molecular probes have been investigated for more accurate pre- and posttreatment assessment of lymphomas but none of these probes was widely accepted and utilized until the emergence of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). FDG-PET or FDG-PET/CT, which combines FDG-PET with CT scanning, is now widely utilized for response assessment of lymphoma after completion of therapy, for pretreatment staging, and, increasingly, also for assessment of response during therapy (therapy monitoring). Particularly for response assessment at therapy conclusion, FDG-PET has been shown to be considerably more accurate than CT or conventional MRI because of its ability to distinguish between viable tumor and necrosis or fibrosis in posttherapy residual mass (es) that are frequently present in patients with lymphoma without any other clinical or biochemical evidence of disease. FDG-PET/CT is therefore the noninvasive modality of choice for response classifications of HL and aggressive NHLs consistent with the recently revised, primarily FDG-PET/CT-based, response criteria for lymphoma. This review will highlight the most important applications of FDG-PET (FDG-PET/CT) in lymphoma emphasizing the strengths and pitfalls of this imaging approach, past and ongoing efforts to standardize the use of FDG-PET, particularly in response assessment and therapy monitoring. Other promising molecular probes for lymphoma imaging will also be briefly discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cheson, B.D., Horning, S.J., Coiffier, B., et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17(4), 1244–53.

    PubMed  CAS  Google Scholar 

  2. Surbone, A., Longo, D.L., DeVita, V.T. Jr., et al. (1988) Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy. Significance and management. J Clin Oncol 6, 832–7.

    Google Scholar 

  3. Canellos, G.P. (1988) Residual mass in lymphoma may not be residual disease. J Clin Oncol 6, 931–3.

    PubMed  CAS  Google Scholar 

  4. Kaplan, W.D., Jochelson, M.S., Herman, T.S., et al. (1990) Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma.J Clin Oncol 8, 1966–70.

    PubMed  CAS  Google Scholar 

  5. Front, D., Bar-Shalom, R., Mor, M., et al. (2000) Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. Radiology 214, 253–7.

    PubMed  CAS  Google Scholar 

  6. Vose, J.M., Bierman, P.J., Anderson, J.R., et al. (1996) Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 14, 2473–9.

    PubMed  CAS  Google Scholar 

  7. Janicek, M., Kaplan, W., Neuberg, D., et al. (1997) Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin’s lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 15, 1631–7.

    PubMed  CAS  Google Scholar 

  8. Juweid, M.E., Stroobants, S., Hoekstra, O.S., et al. (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25, 571–8.

    Article  PubMed  Google Scholar 

  9. Cheson, B.D., Pfistner, B., Juweid, M.E., et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25, 579–86.

    Article  PubMed  Google Scholar 

  10. Juweid, M.E., Wiseman, G.A., Vose, J.M., et al. (2007) Response assessment of aggressive non-Hodgkin’s lymphoma by integrated international workshop criteria and fluorine 18 fluorodeoxyglucose positron emission tomography. J Clin Oncol 23, 4652–61.

    Article  Google Scholar 

  11. Juweid, M.E., Cheson, B.D. (2005) Role of positron emission tomography in lymphoma. J Clin Oncol 23, 4577–80.

    Article  PubMed  Google Scholar 

  12. Seam, P., Juweid, M.E., Cheson, B.D. (2007) The role of FDG-PET scans in patients with lymphoma. Blood 110(10), 3507–16.

    Article  PubMed  CAS  Google Scholar 

  13. Juweid, M.E. (2006) Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 259–65, 510–1.

    Google Scholar 

  14. Juweid, M.E., Cheson, B.D. (2006) Positron emission tomography and assessment of cancer therapy. N Engl J Med 354, 496–507.

    Article  PubMed  CAS  Google Scholar 

  15. Juweid, M.E. (2008) 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma: where is the evidence. J Nucl Med 49(1), 9–12.

    Article  PubMed  Google Scholar 

  16. Friedberg, J.W., Fishman, A., Neuberg, D., et al. (2004) FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 45, 85–92.

    Article  PubMed  Google Scholar 

  17. Moog, F., Bangerter, M., Diederichs, C.G., et al. (1997) Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 203, 795–800.

    PubMed  CAS  Google Scholar 

  18. Moog, F., Bangerter, M., Diederichs, C.G., et al. (1998) Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206, 475–81.

    PubMed  CAS  Google Scholar 

  19. Buchmann, I., Reinhardt, M., Elsner, K., et al. (2001) 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91, 889–99.

    Article  PubMed  CAS  Google Scholar 

  20. Bangerter, M., Moog, F., Buchmann, I. (1998) Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 9, 1117–22.

    Article  PubMed  CAS  Google Scholar 

  21. Jerusalem, G., Beguin, Y., Fassotte, M.-F., et al. (2001) Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Hematologica 86, 266–73.

    CAS  Google Scholar 

  22. Partridge, S., Timothy, A., O’Doherty, M.J., Hain, S.F., Rankin, S., Mikhaeel, G. (2000) 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease: influence on patient management in a single institution. Ann Oncol 11, 1273–9.

    Article  PubMed  CAS  Google Scholar 

  23. Weihrauch, M.R., Re, D., Bischoff, S., et al. (2002) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematol 81, 20–5.

    Article  PubMed  CAS  Google Scholar 

  24. Menzel, C., Döbert, N., Mitrou, P., et al. (2002) Positron emission tomography for the staging of Hodgkin’s lymphoma. Acta Oncologica 41, 430–6.

    Article  PubMed  Google Scholar 

  25. Naumann, R., Beuthien-Baumann, B., Reiss, A., et al. (2004) Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br J Cancer 90, 620–5.

    Article  PubMed  CAS  Google Scholar 

  26. Hutchings, M., Loft, A., Hansen, M., et al. (2006) Positron emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91, 482–9.

    PubMed  Google Scholar 

  27. Schaefer, N.G., Hany, T.F., Taverna, C., et al. (2004) Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging – do we need contrast-enhanced CT. Radiology 232, 823–9.

    Article  PubMed  Google Scholar 

  28. Moog, F., Bangerter, M., Kotzerke, J., Guhlmann, A., Frickhofen, N., Reske, S.N. (1998) 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16, 603–9.

    PubMed  CAS  Google Scholar 

  29. Carr, R., Barrington, S.F., Madan, B., et al. (1998) Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91, 3340–6.

    PubMed  CAS  Google Scholar 

  30. Elstrom, R., Guan, L., Baker, G., et al. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101, 3875–6.

    Article  PubMed  CAS  Google Scholar 

  31. Pakos, E.E., Fotopoulos, A.D., Ioannidis, J.P.A. (2005) 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46, 958–63.

    PubMed  Google Scholar 

  32. Hoffmann, M., Kletter, K., Diemling, M., et al. (1999) Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 10, 1185–9.

    Article  PubMed  CAS  Google Scholar 

  33. Jerusalem, G., Beguin, Y., Najjar, F., et al. (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 12, 825–30.

    Article  PubMed  CAS  Google Scholar 

  34. Bishu, S., Quigley, J.M., Schmitz, J., et al. (2007) F-18-fluoro-deoxy-glucose (FDG) positron emission tomography (PET) in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 48(8), 1531–8.

    Article  PubMed  CAS  Google Scholar 

  35. Kako, S., Izutsu, K., Ohta, Y., et al. (2007) FDG-PET in T-cell and NK-cell neoplasm. Ann Oncol 18, 1685–90.

    Article  PubMed  CAS  Google Scholar 

  36. Juweid, M.E. (2007) Peripheral T-cell ­lymphomas: variably or routinely fluorodeoxyglucose-avid? Commentary in Leuk Lymphoma 48(8), 1455–67.

    Google Scholar 

  37. Allen-Auerbach, M., Quon, A., Weber, W.A., et al. (2004) Comparison between 2-deoxy-2-[(18)F]fluoro-D-glucose positron-emission tomography and positron-emission tomography/computed tomography hard­ware fusion for staging of patients with lymphoma. Mol Imaging Biol 6, 411–6.

    Article  PubMed  Google Scholar 

  38. Rodríguez-Vigil, B., Gómez-León, N., Pinilla, I., et al. (2006) PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 47(10), 1643–8.

    PubMed  Google Scholar 

  39. Elstrom, R.L., Leonard, J.P., Coleman, M., Brown, R.K. (2008) Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 19(10), 1770–3.

    Article  PubMed  CAS  Google Scholar 

  40. Freudenberg, L.S., Antoch, G., Schütt, P., et al. (2004) FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31, 325–9.

    Article  PubMed  CAS  Google Scholar 

  41. de Wit, M., Bumann, D., Beyer, W., et al. (1997) Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 8, 57–60.

    Article  PubMed  Google Scholar 

  42. Jerusalem, G., Beguin, Y., Fassotte, M.F., et al. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94, 429–33.

    PubMed  CAS  Google Scholar 

  43. Zinzani, P.L., Magagnoli, M., Chierichetti, F., et al. (1999) The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 10, 1181–4.

    Article  PubMed  CAS  Google Scholar 

  44. Bangerter, M., Moog, F., Griesshammer, M., et al. (1999) Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 38, 799–804.

    Article  PubMed  CAS  Google Scholar 

  45. Mikhaeel, N.G., Timothy, A.R., Hain, S.F., O’Doherty, M.J. (2000) 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 11(1), 147–50.

    Article  PubMed  Google Scholar 

  46. de Wit, M., Bohuslavizki, K.H., Buchert, R., et al. (2001) 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol 12, 29–37.

    Article  PubMed  Google Scholar 

  47. Naumann, R., Vaic, A., Beuthien-Baumann, B., et al. (2001) Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 115, 793–800.

    Article  PubMed  CAS  Google Scholar 

  48. Weihrauch, M.R., Re, D., Scheidhauer, K., et al. (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98, 2930–4.

    Article  PubMed  CAS  Google Scholar 

  49. Dittman, H., Sokler, M., Kollmannsberger, C., et al. (2001) Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin’s lymphoma. Oncol Rep 8, 1393–9.

    Google Scholar 

  50. Spaepen, K., Stroobants, S., Dupont, P., et al. (2001) Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115, 272–8.

    Article  PubMed  CAS  Google Scholar 

  51. Hueltenschmidt, B., Sautter-Bihl, M.L., Lang, O., et al. (2001) Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 91, 302–10.

    Article  PubMed  CAS  Google Scholar 

  52. Spaepen, K., Stroobants, S., Dupont, P., et al. (2001) Prognostic value of positron emission tomography (PET) with fluorine 18 Fluorode-oxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19, 414–9.

    PubMed  CAS  Google Scholar 

  53. Zijlstra, J.M., Linduer-vander Werf, G., Hoekstra, O.S., Hooft, L., Riphagen, I.I., Huijgens, P.C. (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91, 522–9.

    PubMed  Google Scholar 

  54. Thomas, D.L., Berbaum, K., Bushnell, D.L., Graham, M.M., Juweid, M.E. (2009) Reproducibility of the International Harmoniza-tion Project (IHP)-based interpretation of PET/CT in patients with Hodgkin’s and aggressive non-Hodgkin’s lymphoma. Presented at the Pan-Pacific Lymphoma Conference, June 22–26, 2009, Big Island, HI.

    Google Scholar 

  55. Römer, W., Hanauske, A.-R., Ziegler, S., et al. (1998) Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with Fluorodeoxyglucose. Blood 91, 4464–71.

    PubMed  Google Scholar 

  56. Jerusalem, G., Beguin, Y., Fassotte, M.F., et al. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 85, 613–8.

    PubMed  CAS  Google Scholar 

  57. Spaepen, K., Stroobants, S., Dupont, P., et al. (2001) Early staging positron emission tomography (PET) with fluorine 18 fluorodeoxyglucose ([18F]FDG) predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Blood 98, 726a.

    Google Scholar 

  58. Kostakoglu, L., Coleman, M., Leonard, J.P., et al. (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43, 1018–27.

    PubMed  Google Scholar 

  59. Mikhaeel, N.G., Timothy, A.R., O’Doherty, M.J., Hain, S., Maisey, M.N. (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma-comparison with CT. Leuk Lymphoma 39, 543–53.

    Article  PubMed  CAS  Google Scholar 

  60. Hutchings, M., Mikhaeel, N.G., Fields, P.A., Nunan, T., Timothy, A.R. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16, 1160–8.

    Article  PubMed  CAS  Google Scholar 

  61. Hutchings, M., Loft, A., Hansen, M., et al. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin Lym­phoma. Blood 107, 52–9.

    Article  PubMed  CAS  Google Scholar 

  62. Lin, C., Itti, E., Haioun, C., et al. (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48(10), 1626–32.

    Article  PubMed  Google Scholar 

  63. Weber, W.A. (2007) 18-FDG PET in non-Hodgkin’s lymphoma: qualitative or quantitative? J Nucl Med 48(10), 1580–2.

    Article  PubMed  Google Scholar 

  64. Itti, E., Lin, C., Dupuis, J., et al. (2009) Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 50(4), 527–33.

    Article  PubMed  Google Scholar 

  65. Dupuis, J., Itti, E., Rahmouni, A., et al. (2009) Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol 20(3), 503–7.

    Article  PubMed  CAS  Google Scholar 

  66. Gallamini, A., Hutchings, M., Rigacci, L., et al. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24), 3746–52.

    Article  PubMed  CAS  Google Scholar 

  67. Horning, S.J., Juweid, M.E., Schoder, H., et al. 372 interim positron emission tomography (PET) in diffuse large B-cell lymphoma: independent expert nuclear medicine evaluation of ECOG 3404. Presented at the 50th ASH Annual Meeting and Exposition, December 6–9, 2008, San Francisco, CA.

    Google Scholar 

  68. Cheson, B. (2009) The case against heavy PETing. J Clin Oncol 27(11), 1742–3.

    Article  PubMed  Google Scholar 

  69. Jerusalem, G., Beguin, Y., Fassotte, M.F., et al. (2003) Early detection of relapse by whole-body emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 14, 123–30.

    Article  PubMed  CAS  Google Scholar 

  70. Zinzani, P.L., Stefoni, V., Tani, M., et al. (2009) Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 27(11), 1781–7.

    Article  PubMed  Google Scholar 

  71. Lapela, M., Leskinen, S., Minn, H.R., et al. (1995) Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86, 3522–7.

    PubMed  CAS  Google Scholar 

  72. Schöder, H., Noy, A., Gönen, M., et al. (2005) Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23, 4643–51.

    Article  PubMed  Google Scholar 

  73. Buck, A.K., Bommer, M., Stilgenbauer, S., et al. (2006) Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66, 11055–61.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA

    Malik E. Juweid

Authors
  1. Malik E. Juweid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malik E. Juweid .

Editor information

Editors and Affiliations

  1. Dept. Radiology, University of Iowa, Hawkins Drive 200, Iowa City, 52242-1009, Iowa, USA

    Malik E. Juweid

  2. , Dept. Nuclear Medicine & PET Research, VU University Medical Centre, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands

    Otto S. Hoekstra

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Humana Press

About this protocol

Cite this protocol

Juweid, M.E. (2011). FDG-PET/CT in Lymphoma. In: Juweid, M., Hoekstra, O. (eds) Positron Emission Tomography. Methods in Molecular Biology, vol 727. Humana Press. https://doi.org/10.1007/978-1-61779-062-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-062-1_1

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-061-4

  • Online ISBN: 978-1-61779-062-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation